Continuing Enhanced National Surveillance for Prion Diseases in the United States

The Continuing Enhanced National Surveillance for Prion Diseases in the United States opportunity is administered by the U.S. Department of Health and Human Services through the Centers for Disease Control and Prevention, specifically within the National Center for Emerging and Zoonotic Infectious Diseases. This federal initiative builds on a long-standing national effort, dating back to 1997, to monitor, diagnose, and track prion diseases, which are rare but fatal neurodegenerative conditions also known as transmissible spongiform encephalopathies. The program reflects the CDC’s ongoing commitment to strengthening public health surveillance infrastructure and ensuring rapid identification of emerging infectious disease threats within the United States. The primary purpose of this cooperative agreement is to continue and enhance national surveillance activities for human prion diseases. The program aims to confirm suspected and clinically diagnosed cases while also monitoring for new or emerging variants of prion diseases. Because these diseases are uniformly fatal and can only be definitively diagnosed through specialized brain tissue analysis, the CDC supports a centralized, highly specialized diagnostic center capable of performing advanced laboratory techniques. This center serves as a national resource, supporting clinicians, public health officials, and researchers by providing accurate diagnostic confirmation and contributing to epidemiological tracking. Funding under this opportunity is intended to support the operation and advancement of this specialized surveillance and diagnostic center. Allowable uses of funds include conducting laboratory analyses, maintaining surveillance systems, supporting epidemiological investigations, and collaborating with CDC experts to interpret data and identify trends. The cooperative agreement structure indicates that the CDC will maintain substantial involvement in program activities, including technical guidance, data sharing, and coordination of surveillance outcomes. There are no cost sharing or matching requirements specified for this funding opportunity, which lowers the financial barrier to participation for eligible applicants. Eligibility for this opportunity is broad and includes a wide range of public and private entities. Eligible applicants encompass state governments, local governments such as counties and municipalities, tribal governments and organizations, institutions of higher education, nonprofit organizations both with and without 501c3 status, and for profit entities including small businesses. This inclusive eligibility framework allows for a diverse set of applicants, though the nature of the program suggests that only organizations with specialized laboratory and epidemiological capabilities will be competitive. The application process is expected to follow standard federal grant submission procedures through electronic systems, with applications required to be submitted by the specified deadline. While detailed application components are not provided in the forecast notice, typical submissions for CDC cooperative agreements include technical proposals, budgets, organizational capacity descriptions, and compliance documentation. Applications must be submitted electronically by 11:59 pm Eastern Time on the due date. The review process will likely assess scientific and technical merit, organizational expertise, and the ability to carry out national surveillance activities effectively. The timeline for this opportunity indicates that it is currently in a forecast stage, with an estimated posting date in late December and an application deadline in late March of the following year. Awards are anticipated to be made by the end of August, with the project start date aligned to the award date. The total program funding is substantial, supporting a single award with a ceiling of twenty five million dollars and a floor of three million dollars. This suggests a large scale, multi year effort focused on maintaining national surveillance capacity. The program does not explicitly state recurrence, but its historical continuity suggests that similar funding opportunities may be issued periodically to sustain this critical public health function.